日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A Prolonged Nightly Fasting Plus Telehealth Coaching Intervention (PNF+) for Men on Androgen Deprivation Therapy for PCa: A Pilot Feasibility Randomized Controlled Trial

一项针对接受雄激素剥夺疗法治疗前列腺癌的男性患者的延长夜间禁食加远程医疗指导干预（PNF+）：一项试点可行性随机对照试验

期刊:Nutrients
影响因子:5
doi:10.3390/nu18071166
Wen, Kuang-Yi; Freedman, Julianne; Zarrabi, Kevin Kayvan; Slamon, Rachel; Smith, Rita; Liang, Jessica; Mille, Patrick; Tester, William J; Kelly, William
肿瘤
前列腺癌
肿瘤免疫
免疫/内分泌
发表日期：2026
文献求助 收藏

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

帕博利珠单抗联合阿扎胞苷进行表观遗传修饰可重塑铂耐药性上皮性卵巢癌的肿瘤微环境：一项 II 期非随机临床试验

期刊:
影响因子:
doi:10.1038/s43856-026-01404-0
Landon, Blair V; Boland, Julia L; Wahner Hendrickson, Andrea E; Armstrong, Deborah K; Winterhoff, Boris; Wehr, Jaime; Annapragada, Akshaya V; Cherry, Christopher; Balan, Archana; Kaleka, Guneet; Velculescu, Victor E; Baylin, Stephen B; Zahnow, Cynthia A; Slamon, Dennis J; Konecny, Gottfried E; Anagnostou, Valsamo; Glaspy, John A
肿瘤
表观遗传
肿瘤免疫
卵巢癌
肿瘤微环境
发表日期：2026
文献求助 收藏

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

瑞博西尼联合内分泌治疗激素受体阳性/ERBB2阴性早期乳腺癌：NATALEE随机临床试验的4年结果

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2025.3700
Fasching, Peter A; Stroyakovskiy, Daniil; Yardley, Denise A; Huang, Chiun-Sheng; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Xu, Binghe; Loi, Sherene; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Hortobagyi, Gabriel N; Slamon, Dennis J; Fresco, Rodrigo; Zarate, Juan Pablo; Li, Zheng; Waters, Sorcha; Hurvitz, Sara A
肿瘤
肿瘤免疫
ERBB2
信号转导
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial

接受瑞博西尼联合非甾体类芳香化酶抑制剂治疗的 HR+/HER2- 早期乳腺癌患者的健康相关生活质量：NATALEE 试验结果

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-1724
Fasching, Peter A; Slamon, Dennis; Nowecki, Zbigniew; Kukielka-Budny, Bozena; Stroyakovskiy, Daniil; Yardley, Denise A; Huang, Chiun-Sheng; Chan, Arlene; Chia, Stephen; Martín, Miguel; Rugo, Hope S; Loi, Sherene; Hurvitz, Sara; Untch, Michael; Afenjar, Karen; Fresco, Rodrigo; Danyliv, Andriy; Ferrusi, Ilia; Li, Zheng; Hortobagyi, Gabriel
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

辅助性利博西尼联合非甾体类芳香化酶抑制剂治疗HR阳性/HER2阴性早期乳腺癌患者：NATALEE研究疗效结果的5年随访及更新的总生存期

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105858
Crown, J; Stroyakovskii, D; Yardley, D A; Huang, C-S; Fasching, P A; Bardia, A; Chia, S; Im, S-A; Martin, M; Xu, B; Barrios, C H; Untch, M; Moroose, R; Hurvitz, S A; Hortobagyi, G N; Slamon, D J; Visco, F; Spera, G; Zarate, J P; Halligan, D; Li, Z; Loi, S
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

预测年轻乳腺癌患者化疗和抗HER2治疗后卵巢功能的丧失

期刊:Jnci-Journal of the National Cancer Institute
影响因子:7.2
doi:10.1093/jnci/djaf198
Lambertini, Matteo; Allegranza, Deirdre; Laubender, Ruediger P; Harbeck, Nadia; Swain, Sandra M; Geyer, Charles E; Slamon, Dennis J; Bobba, Gabriella; Lambertini, Chiara; de Haas, Sanne; Restuccia, Eleonora; Vaz-Luis, Ines; Cameron, David A; Krop, Ian E; Winer, Eric P; Anderson, Richard A
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

体重指数作为早期乳腺癌患者辅助紫杉烷类化疗疗效的预测因素：来自GEICAM西班牙乳腺癌研究组和TRIO肿瘤转化研究组的辅助治疗研究汇总分析

期刊:International Journal of Cancer
影响因子:4.7
doi:10.1002/ijc.35432
García-Saenz, José A; Spera, Gonzalo; Pollán, Marina; Bermejo, Begoña; Ruiz-Borrego, Manuel; Chan, Arlene; Martín, Miguel; Guerrero-Zotano, Ángel; Calvo, Lourdes; Rodríguez-Lescure, Álvaro; Marín, María; Chap, Linnea; Crown, John; Pienkowski, Tadeusz; Bee, Valerie; Casas, Maribel; Polonio, Óscar; Bezares, Susana; Slamon, Dennis
TRIO
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

乳腺癌辅助化疗试验中，中期终点可作为长期疗效的替代指标

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyaf263
Blasco, Andrea; López-Tarruella, Sara; Urruticoechea, Ander; Carrasco, Eva; Spera, Gonzalo; Martín, Miguel; Bermejo, Begoña; Chap, Linnea; Ruiz-Borrego, Manuel; Crown, John; García-Saenz, Jose A; Chan, Arlene; Guerrero-Zotano, Ángel; Semiglazov, Vladimir; Calvo, Lourdes; Pienkowski, Tadeusz; Herranz, Jesús; Slamon, Dennis
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer

首个 CDK4/6 抑制剂获批十年后：回顾帕博西尼从发现到获批的历程以及 CDK 抑制剂在乳腺癌治疗中的下一步发展

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-025-01175-z
Finn, Richard S; Rugo, Hope S; Cortes, Javier; Loibl, Sibylle; Foley, Grace; Gauthier, Eric; Wang, Yao; Kim, Sindy; Anders, Lars; Slamon, Dennis J
CDK4
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

A smart pill bottle and text messaging intervention for promoting medication adherence in patients with chronic myeloid leukemia: a pilot study of txt4 TKI

一项利用智能药瓶和短信干预提高慢性粒细胞白血病患者用药依从性的试点研究：txt4 TKI

期刊:Supportive Care in Cancer
影响因子:3
doi:10.1007/s00520-025-09537-z
Wen, Kuang-Yi; Palmisiano, Neil; Smith, Rita; Slamon, Rachel; Keiffer, Gina; Fidler, Christian; Kasner, Margaret; Wilde, Lindsay
白血病
细胞生物学
粒细胞
发表日期：2025
文献求助 收藏